IMMUNOPROLIFERATIVE DISORDERS
Clinical trials for IMMUNOPROLIFERATIVE DISORDERS explained in plain language.
Never miss a new study
Get alerted when new IMMUNOPROLIFERATIVE DISORDERS trials appear
Sign up with your email to follow new studies for IMMUNOPROLIFERATIVE DISORDERS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells with 'Off Switch' tested for tough leukemia
Disease control OngoingThis early-phase trial tests a new type of CAR-T cell therapy for people with relapsed or hard-to-treat acute lymphoblastic leukemia. The cells are engineered to recognize and kill leukemia cells, but also include a safety switch that can be turned on to calm them down if side ef…
Matched conditions: IMMUNOPROLIFERATIVE DISORDERS
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered immune cells take aim at tough lymphomas in first human test
Disease control OngoingThis early-phase trial tests a new type of immunotherapy for people with Hodgkin lymphoma or cutaneous T-cell lymphoma that has returned or not responded to standard treatments. The therapy uses the patient's own T cells, which are genetically modified to recognize and attack can…
Matched conditions: IMMUNOPROLIFERATIVE DISORDERS
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Supercharged immune cells aim to stop lymphoma comeback
Disease control OngoingThis early-phase trial tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma who have had a stem cell transplant. The treatment uses the patient's own T cells, which are modified in a lab to recognize and attack cancer cells that carry a protein called CD30. The m…
Matched conditions: IMMUNOPROLIFERATIVE DISORDERS
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Supercharged immune cells take on tough lymphomas
Disease control OngoingThis study tests a new treatment for people with Hodgkin or non-Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment involves taking a patient's own T cells (a type of immune cell), adding a gene that helps them recognize and attack lymphoma cell…
Matched conditions: IMMUNOPROLIFERATIVE DISORDERS
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Engineered immune cells with an emergency brake tested in lymphoma
Disease control OngoingThis early-phase study tests a new type of CAR T-cell therapy for people with B-cell lymphoma that has come back or not responded to treatment. The cells are engineered to target and kill cancer cells, but also include a safety switch that can be activated to reduce severe side e…
Matched conditions: IMMUNOPROLIFERATIVE DISORDERS
Phase: PHASE1 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC